46,82 $
0,26 % gestern
NYSE, 3. Dezember, 22:10 Uhr
ISIN
NL0012169213
Symbol
QGEN
Berichte

QIAGEN NV Aktie News

Neutral
Seeking Alpha
etwa 15 Stunden alt
Qiagen N.V. (QGEN) Presents at Evercore 8th Annual Healthcare Conference Transcript
Neutral
Seeking Alpha
2 Tage alt
Qiagen N.V. (QGEN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Neutral
Seeking Alpha
13 Tage alt
Qiagen N.V. ( QGEN ) Deep Dive Into Sample Technologies: Leadership, Innovation and Future Expansion November 21, 2025 9:00 AM EST Company Participants Domenica Martorana - Associate Director of Global Investor Relations Thierry Bernard - CEO, MD & Member of Management Board Daniel Wendorff John Gilardi - VP & Head of Corporate Communications Michael Scheffler Nitin Sood - Senior VP & Head of P...
Neutral
Seeking Alpha
15 Tage alt
Qiagen N.V. ( QGEN ) Jefferies London Healthcare Conference 2025 November 19, 2025 5:30 AM EST Company Participants Roland Sackers - CFO, MD & Member of Management Board Daniel Wendorff John Gilardi - VP & Head of Corporate Communications Conference Call Participants Tycho Peterson - Jefferies LLC, Research Division Presentation Tycho Peterson Jefferies LLC, Research Division Welcome, everybody.
Positiv
Proactive Investors
16 Tage alt
Shares in CelLBxHealth PLC (AIM:CLBX, NSX:ANPCY, OTCQB:ANPCF) climbed 7% to 1.93p after the company unveiled a collaboration with Qiagen designed to bring its Parsortix circulating tumour cell platform to a wider range of pharmaceutical partners. The agreement gives Qiagen the ability to bundle Parsortix into projects alongside its own molecular technologies, including polymerase chain reaction...
Positiv
Proactive Investors
16 Tage alt
CelLBxHealth PLC (AIM:CLBX, NSX:ANPCY, OTCQB:ANPCF) has agreed a collaboration and co-marketing deal with Qiagen that will allow the diagnostics group to promote the UK company's Parsortix system to drugmakers, opening the door to new projects in circulating tumour cell research and early diagnostic development. The non-exclusive agreement enables Qiagen to offer the Parsortix platform to its p...
Neutral
Seeking Alpha
17 Tage alt
Qiagen N.V. ( QGEN ) 7th Annual Wolfe Research Healthcare Conference November 17, 2025 12:40 PM EST Company Participants Thierry Bernard - CEO, MD & Member of Management Board Conference Call Participants Douglas Schenkel - Wolfe Research, LLC Presentation Douglas Schenkel Wolfe Research, LLC All right.
Neutral
Business Wire
24 Tage alt
GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the debut of QIAsymphony Connect, the next generation of QIAGEN's widely adopted automated nucleic acid purification platform, at the 2025 AMP (Association for Molecular Pathology) annual meeting from November 11-15 in Boston. The first public introduc...

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen